|
HU228446B1
(en)
|
1996-04-12 |
2013-03-28 |
Warner Lambert Co |
Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof
|
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
|
TW436485B
(en)
*
|
1997-08-01 |
2001-05-28 |
American Cyanamid Co |
Substituted quinazoline derivatives
|
|
ATE368665T1
(de)
|
1997-08-22 |
2007-08-15 |
Astrazeneca Ab |
Oxindolylchinazolinderivate als angiogenesehemmer
|
|
CZ2001584A3
(cs)
|
1998-08-18 |
2002-06-12 |
The Regents Of The University Of California |
Prevence tvorby hlenu v dýchacích cestách podáváním antagonistů EGF-R
|
|
US6184226B1
(en)
|
1998-08-28 |
2001-02-06 |
Scios Inc. |
Quinazoline derivatives as inhibitors of P-38 α
|
|
BRPI9914164B8
(pt)
|
1998-09-29 |
2021-05-25 |
American Cyanamid Co |
compostos de 3-ciano quinolina
|
|
DK1119567T3
(da)
|
1998-10-08 |
2005-07-25 |
Astrazeneca Ab |
Quinazolinderivater
|
|
KR20020068261A
(ko)
*
|
1999-02-27 |
2002-08-27 |
베링거 잉겔하임 파르마 카게 |
티로신 키나제에 의해 매개되는 신호 변환에 대한 억제효과를 갖는 4-아미노-퀴나졸린 및 퀴놀린 유도체
|
|
PT1171440E
(pt)
*
|
1999-04-21 |
2004-07-30 |
Wyeth Corp |
3-ciano-¬1,7|,¬1,5|, e ¬1,8|-naftiridinas substituidas inibidoras de tirosina quinases
|
|
CA2375259C
(en)
*
|
1999-06-21 |
2009-04-28 |
Boehringer Ingelheim Pharma Kg |
Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
|
PL203782B1
(pl)
|
1999-11-05 |
2009-11-30 |
Astrazeneca Ab |
Pochodne chinazoliny,sposoby ich wytwarzania,ich kompozycje farmaceutyczne oraz ich zastosowania
|
|
AU779695B2
(en)
|
2000-04-07 |
2005-02-10 |
Astrazeneca Ab |
Quinazoline compounds
|
|
WO2001077104A1
(de)
*
|
2000-04-08 |
2001-10-18 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
|
US6627634B2
(en)
|
2000-04-08 |
2003-09-30 |
Boehringer Ingelheim Pharma Kg |
Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
|
|
UA73993C2
(uk)
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Хіназолінові похідні для лікування пухлин та фармацевтична композиція
|
|
EE200200715A
(et)
*
|
2000-06-28 |
2004-08-16 |
Astrazeneca Ab |
Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena
|
|
AU2001278609B2
(en)
|
2000-08-21 |
2005-04-14 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
US6403580B1
(en)
|
2000-08-26 |
2002-06-11 |
Boehringer Ingelheim Pharma Kg |
Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
|
DE10042060A1
(de)
*
|
2000-08-26 |
2002-03-07 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
|
US6617329B2
(en)
|
2000-08-26 |
2003-09-09 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines and their use as medicaments
|
|
DE10042062A1
(de)
*
|
2000-08-26 |
2002-03-07 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Hertellung
|
|
US6740651B2
(en)
|
2000-08-26 |
2004-05-25 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
|
|
US6653305B2
(en)
|
2000-08-26 |
2003-11-25 |
Boehringer Ingelheim Pharma Kg |
Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
|
|
US6656946B2
(en)
|
2000-08-26 |
2003-12-02 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
|
|
AU2001292138A1
(en)
|
2000-10-13 |
2002-04-22 |
Astrazeneca Ab |
Quinazoline derivatives with anti-tumour activity
|
|
WO2002030926A1
(en)
|
2000-10-13 |
2002-04-18 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
US7019012B2
(en)
|
2000-12-20 |
2006-03-28 |
Boehringer Ingelheim International Pharma Gmbh & Co. Kg |
Quinazoline derivatives and pharmaceutical compositions containing them
|
|
US6562319B2
(en)
|
2001-03-12 |
2003-05-13 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
|
|
EP1381599B1
(en)
|
2001-04-19 |
2008-09-24 |
Astrazeneca AB |
Quinazoline derivatives
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
|
US20040044014A1
(en)
|
2002-04-19 |
2004-03-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
|
|
DE10217689A1
(de)
*
|
2002-04-19 |
2003-11-13 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
|
|
US20050276812A1
(en)
|
2004-06-01 |
2005-12-15 |
Genentech, Inc. |
Antibody-drug conjugates and methods
|
|
DE10221018A1
(de)
|
2002-05-11 |
2003-11-27 |
Boehringer Ingelheim Pharma |
Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
|
|
DE10230751A1
(de)
*
|
2002-07-09 |
2004-01-22 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und EGFR-Kinase-Hemmern
|
|
EP2263691B1
(en)
|
2002-07-15 |
2012-08-29 |
F.Hoffmann-La Roche Ag |
Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4)
|
|
EP1542989B1
(en)
|
2002-07-31 |
2007-04-18 |
Critical Outcome Technologies, Inc. |
Protein tyrosine kinase inhibitors
|
|
WO2004029207A2
(en)
|
2002-09-27 |
2004-04-08 |
Xencor Inc. |
Optimized fc variants and methods for their generation
|
|
AU2003273675A1
(en)
|
2002-10-09 |
2004-05-04 |
Wayne R. Danter |
Protein tyrosine kinase inhibitors
|
|
CA2529611C
(en)
|
2002-12-20 |
2009-12-15 |
Pfizer Products Inc. |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
|
US7109337B2
(en)
|
2002-12-20 |
2006-09-19 |
Pfizer Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
|
JP2006515871A
(ja)
*
|
2003-01-23 |
2006-06-08 |
ティー．ケイ． シグナル リミテッド |
上皮増殖因子受容体チロシンキナーゼの不可逆阻害剤ならびにその使用
|
|
US7223749B2
(en)
|
2003-02-20 |
2007-05-29 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
MXPA05012939A
(es)
|
2003-05-30 |
2006-05-17 |
Astrazeneca Uk Ltd |
Procedimiento.
|
|
CA2527832A1
(en)
*
|
2003-06-10 |
2004-12-23 |
F. Hoffmann-La Roche Ag |
1.3.4-triaza-phenalene and 1,3,4,6-tetraazaphenalene derivatives
|
|
US8309562B2
(en)
|
2003-07-03 |
2012-11-13 |
Myrexis, Inc. |
Compounds and therapeutical use thereof
|
|
CN1984660B
(zh)
|
2003-07-03 |
2010-12-15 |
美瑞德生物工程公司 |
作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉
|
|
KR101028952B1
(ko)
|
2003-08-14 |
2011-04-12 |
어레이 바이오파마 인크. |
수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체
|
|
US7501427B2
(en)
|
2003-08-14 |
2009-03-10 |
Array Biopharma, Inc. |
Quinazoline analogs as receptor tyrosine kinase inhibitors
|
|
AU2004270016A1
(en)
*
|
2003-09-11 |
2005-03-17 |
Hadasit Medical Research Services And Development Ltd. |
Radiolabeled anilinoquinazolines and their use in radioimaging and radiotherapy
|
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US7456189B2
(en)
|
2003-09-30 |
2008-11-25 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
|
|
DE10349113A1
(de)
|
2003-10-17 |
2005-05-12 |
Boehringer Ingelheim Pharma |
Verfahren zur Herstellung von Aminocrotonylverbindungen
|
|
CN107213469A
(zh)
|
2003-11-06 |
2017-09-29 |
西雅图基因公司 |
能够与配体偶联的单甲基缬氨酸化合物
|
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
US7875624B2
(en)
*
|
2004-02-20 |
2011-01-25 |
Novartis Vaccines And Diagnostics, Inc. |
Modulating and measuring cellular adhesion
|
|
PT1733056E
(pt)
|
2004-03-31 |
2013-08-29 |
Gen Hospital Corp |
Método para determinar a responsividade do cancro a tratamentos visando o receptor do factor de crescimento epidérmico
|
|
EP2543376A1
(en)
|
2004-04-08 |
2013-01-09 |
Targegen, Inc. |
Benzotriazine inhibitors of kinases
|
|
NZ550796A
(en)
|
2004-05-06 |
2010-07-30 |
Warner Lambert Co |
4-phenylamino-quinazolin-6-yl-amides
|
|
WO2005111024A1
(en)
|
2004-05-14 |
2005-11-24 |
Pfizer Products Inc. |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
|
MXPA06013164A
(es)
|
2004-05-14 |
2007-02-13 |
Pfizer Prod Inc |
Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
|
|
BRPI0510963A
(pt)
|
2004-05-14 |
2007-11-20 |
Pfizer Prod Inc |
derivados pirimidina para o tratamento do crescimento anormal de células
|
|
CN103172731A
(zh)
|
2004-07-15 |
2013-06-26 |
赞科股份有限公司 |
优化的Fc变体
|
|
KR101270829B1
(ko)
|
2004-09-23 |
2013-06-07 |
제넨테크, 인크. |
시스테인 유전자조작 항체 및 접합체
|
|
US20070054916A1
(en)
*
|
2004-10-01 |
2007-03-08 |
Amgen Inc. |
Aryl nitrogen-containing bicyclic compounds and methods of use
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
DK1817340T3
(da)
|
2004-11-12 |
2012-08-13 |
Xencor Inc |
Fc-varianter med ændret binding til fcrn
|
|
WO2006064196A1
(en)
|
2004-12-14 |
2006-06-22 |
Astrazeneca Ab |
Pyrazolopyrimidine compounds as antitumor agents
|
|
KR100735639B1
(ko)
*
|
2004-12-29 |
2007-07-04 |
한미약품 주식회사 |
암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
|
|
EP1833482A4
(en)
|
2005-01-03 |
2011-02-16 |
Myriad Genetics Inc |
COMPOUNDS AND ITS THERAPEUTIC USE
|
|
US8258145B2
(en)
|
2005-01-03 |
2012-09-04 |
Myrexis, Inc. |
Method of treating brain cancer
|
|
UA94899C2
(ru)
|
2005-01-21 |
2011-06-25 |
Дженентек, Инк. |
Фиксированное дозирование антител к her
|
|
DK1850874T3
(da)
|
2005-02-23 |
2013-11-11 |
Genentech Inc |
Forlængelse af tid til sygdomsprogression eller overlevelse for ovariecancer ved anvendelse af pertuzumab
|
|
CA2606207C
(en)
|
2005-04-19 |
2014-11-18 |
Smithkline Beecham (Cork) Limited |
Pharmaceutical composition
|
|
US7557190B2
(en)
|
2005-07-08 |
2009-07-07 |
Xencor, Inc. |
Optimized proteins that target Ep-CAM
|
|
US7820683B2
(en)
|
2005-09-20 |
2010-10-26 |
Astrazeneca Ab |
4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer
|
|
AU2006299429B2
(en)
|
2005-10-03 |
2012-02-23 |
Xencor, Inc. |
Fc variants with optimized Fc receptor binding properties
|
|
NZ567851A
(en)
|
2005-11-01 |
2011-09-30 |
Targegen Inc |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
|
JP5688877B2
(ja)
|
2005-11-11 |
2015-03-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
癌疾患の治療用キナゾリン誘導体
|
|
MX2008015004A
(es)
|
2006-05-26 |
2008-12-05 |
Abbott Lab |
Inhibidores de cinasas de tipo polo.
|
|
JP5825756B2
(ja)
|
2006-08-14 |
2015-12-02 |
ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． |
Ｃｄ１９を標的とする最適化抗体
|
|
WO2008033782A2
(en)
|
2006-09-12 |
2008-03-20 |
Genentech, Inc. |
Methods and compositions for the diagnosis and treatment of lung cancer using pdgfra, kit or kdr gene as genetic marker
|
|
DK2068880T3
(da)
|
2006-09-18 |
2012-07-23 |
Boehringer Ingelheim Int |
Fremgangsmåde til behandling af cancer, der huser EGFR-mutationer
|
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
|
EA200901041A1
(ru)
|
2007-02-06 |
2010-02-26 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
|
|
BRPI0808418A2
(pt)
|
2007-03-02 |
2014-07-22 |
Genentech, Inc |
Predição de resposta a um inibidor de her
|
|
DK2176298T3
(en)
|
2007-05-30 |
2018-02-12 |
Xencor Inc |
Methods and compositions for inhibiting CD32B-expressing cells
|
|
ES2583377T3
(es)
|
2007-06-08 |
2016-09-20 |
Genentech, Inc. |
Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2
|
|
EP2190293A4
(en)
*
|
2007-09-28 |
2011-11-09 |
Absolute Science Inc |
COMPOUNDS AND METHOD FOR THE TREATMENT OF DISEASES MEDIATED BY ZINC MATRIX METALLOPROTEASE
|
|
WO2009046606A1
(en)
*
|
2007-10-11 |
2009-04-16 |
Shanghai Institute Of Materia Medica, Cas |
Pyrimidinyl-propionic acid derivatives and their use as ppar agonists
|
|
PL2808343T3
(pl)
|
2007-12-26 |
2019-11-29 |
Xencor Inc |
Warianty Fc ze zmienionym wiązaniem do FcRn
|
|
EP2225226B1
(en)
|
2007-12-26 |
2016-08-17 |
Critical Outcome Technologies, Inc. |
Compounds and their use in a method for treatment of cancer
|
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
|
|
JP5336516B2
(ja)
|
2008-02-07 |
2013-11-06 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
スピロ環式複素環化合物、該化合物を含む医薬品、その使用及びその製造方法
|
|
US12492253B1
(en)
|
2008-02-25 |
2025-12-09 |
Xencor, Inc. |
Anti-human C5 antibodies
|
|
BRPI0912170A2
(pt)
|
2008-05-13 |
2015-10-13 |
Astrazeneca Ab |
composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente
|
|
EP2288727B1
(en)
|
2008-05-14 |
2013-07-10 |
Genomic Health, Inc. |
Predictors of patient response to treatment with egf receptor inhibitors
|
|
EP3023426A1
(en)
|
2008-07-17 |
2016-05-25 |
Critical Outcome Technologies, Inc. |
Thiosemicarbazone inhibitor compounds and cancer treatment methods
|
|
CA2733153C
(en)
|
2008-08-08 |
2016-11-08 |
Boehringer Ingelheim International Gmbh |
Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
|
|
ITMI20082336A1
(it)
*
|
2008-12-29 |
2010-06-30 |
Univ Parma |
Composti inibitori irreversibili di egfr con attivita' antiproliferativa
|
|
AU2010221818A1
(en)
*
|
2009-03-11 |
2011-10-06 |
Auckland Uniservices Limited |
Prodrug forms of kinase inhibitors and their use in therapy
|
|
NZ594665A
(en)
|
2009-03-20 |
2013-08-30 |
Genentech Inc |
Bispecific anti-her antibodies
|
|
HUE044629T2
(hu)
|
2009-07-06 |
2019-11-28 |
Boehringer Ingelheim Int |
Eljárás BIBW2992, annak sói, valamint e hatóanyagot tartalmazó szilárd gyógyászati készítmények szárítására
|
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
RU2568639C2
(ru)
*
|
2009-09-02 |
2015-11-20 |
Окленд Юнисервисиз Лимитед |
Ингибиторы киназы, их пролекарственные формы и их применение в терапии
|
|
CN102612374A
(zh)
|
2009-11-12 |
2012-07-25 |
霍夫曼-拉罗奇有限公司 |
提升树突棘密度的方法
|
|
MX2012006406A
(es)
|
2009-12-04 |
2012-07-25 |
Genentech Inc |
Anticuerpos multiespecificos, analogos de anticuerpo, composiciones y metodos.
|
|
US8461328B2
(en)
|
2010-01-12 |
2013-06-11 |
Genentech, Inc. |
Tricyclic heterocyclic compounds, compositions and methods of use thereof
|
|
MX2012008958A
(es)
|
2010-02-18 |
2012-08-23 |
Genentech Inc |
Antagonista de neurogulina y usos de los mismos para el tratamiento contra el cancer.
|
|
WO2011107664A1
(en)
|
2010-03-04 |
2011-09-09 |
Hospital District Of Southwest Finland |
Method for selecting patients for treatment with an egfr inhibitor
|
|
US20130096104A1
(en)
|
2010-03-17 |
2013-04-18 |
Genentech, Inc. |
Imidazopyridine compounds, compositions and methods of use
|
|
MX341925B
(es)
|
2010-03-29 |
2016-09-07 |
Zymeworks Inc |
Anticuerpos con funcion efectora suprimida o mejorada.
|
|
US8987272B2
(en)
|
2010-04-01 |
2015-03-24 |
Critical Outcome Technologies Inc. |
Compounds and method for treatment of HIV
|
|
CN103038643A
(zh)
|
2010-04-16 |
2013-04-10 |
基因泰克公司 |
作为pi3k/akt激酶途径抑制剂效能的预测性生物标记的foxo3a
|
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
|
CA2808236A1
(en)
|
2010-08-31 |
2012-03-08 |
Genentech, Inc. |
Biomarkers and methods of treatment
|
|
RU2013114352A
(ru)
|
2010-09-15 |
2014-10-20 |
Ф. Хоффманн-Ля Рош Аг |
Азабензотиазолы, композиции и способы применения
|
|
WO2012060847A1
(en)
|
2010-11-07 |
2012-05-10 |
Targegen, Inc. |
Compositions and methods for treating myelofibrosis
|
|
EP2637692A4
(en)
|
2010-11-12 |
2014-09-10 |
Scott & White Healthcare |
ANTIBODIES TO THE ENDOTHELIAL TUMOR MARKER 8
|
|
CA2817785A1
(en)
|
2010-11-19 |
2012-05-24 |
Toby Blench |
Pyrazolopyridines and pyrazolopyridines and their use as tyk2 inhibitors
|
|
CN102485735B
(zh)
*
|
2010-12-02 |
2014-09-24 |
东莞南方医大代谢医学研发有限公司 |
6-果糖氨-4-芳胺基喹唑啉衍生物及其用途
|
|
WO2012085176A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
|
|
AU2012225693A1
(en)
|
2011-03-04 |
2013-09-19 |
Newgen Therapeutics, Inc. |
Alkyne substituted quinazoline compound and methods of use
|
|
EP2683740B1
(en)
|
2011-03-10 |
2018-07-04 |
Omeros Corporation |
Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
|
|
WO2012155339A1
(zh)
*
|
2011-05-17 |
2012-11-22 |
江苏康缘药业股份有限公司 |
4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
|
|
WO2013007765A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Fused tricyclic compounds for use as inhibitors of janus kinases
|
|
WO2013007768A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
|
|
WO2013024011A1
(en)
|
2011-08-12 |
2013-02-21 |
F. Hoffmann-La Roche Ag |
Indazole compounds, compositions and methods of use
|
|
AU2012295394B2
(en)
|
2011-08-12 |
2016-04-14 |
Omeros Corporation |
Anti-FZD10 monoclonal antibodies and methods for their use
|
|
KR20140057326A
(ko)
|
2011-08-17 |
2014-05-12 |
제넨테크, 인크. |
뉴레귤린 항체 및 그의 용도
|
|
MX2014002949A
(es)
|
2011-09-20 |
2014-04-30 |
Hoffmann La Roche |
Compuesto de imidazopiridina, composiciones y metodos de uso.
|
|
IN2014CN03469A
(enExample)
*
|
2011-11-21 |
2015-07-03 |
Basf Se |
|
|
RU2019103083A
(ru)
|
2011-11-30 |
2019-03-22 |
Дженентек, Инк. |
МУТАЦИИ ErbB3 ПРИ РАКЕ
|
|
CN104379602B
(zh)
|
2012-03-08 |
2017-05-03 |
哈洛齐梅公司 |
具有条件活性的抗表皮生长因子受体抗体及其使用方法
|
|
WO2013148315A1
(en)
|
2012-03-27 |
2013-10-03 |
Genentech, Inc. |
Diagnosis and treatments relating to her3 inhibitors
|
|
EP2958592A1
(en)
|
2013-02-22 |
2015-12-30 |
F. Hoffmann-La Roche AG |
Methods of treating cancer and preventing drug resistance
|
|
RU2015137610A
(ru)
|
2013-03-06 |
2017-04-10 |
Дженентек, Инк. |
Способы лечения и профилактики лекарственной резистентности злокачественных опухолей
|
|
EP2970307B1
(en)
|
2013-03-13 |
2020-03-11 |
Genentech, Inc. |
Pyrazolo compounds and uses thereof
|
|
BR112015022576A2
(pt)
|
2013-03-14 |
2017-10-24 |
Genentech Inc |
produto farmacêutico e seu uso, kit e método para tratar uma disfunção hiperproliferativa
|
|
HK1220916A1
(zh)
|
2013-03-14 |
2017-05-19 |
基因泰克公司 |
治疗癌症和预防癌症药物抗性的方法
|
|
CN105339001A
(zh)
|
2013-03-15 |
2016-02-17 |
基因泰克公司 |
治疗癌症和预防癌症耐药性的方法
|
|
US9505767B2
(en)
|
2013-09-05 |
2016-11-29 |
Genentech, Inc. |
Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors
|
|
SG11201601770YA
(en)
|
2013-09-12 |
2016-04-28 |
Halozyme Inc |
Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
|
|
SG11201510740YA
(en)
|
2013-09-17 |
2016-01-28 |
Obi Pharma Inc |
Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
|
|
TW201605857A
(zh)
|
2013-10-03 |
2016-02-16 |
赫孚孟拉羅股份公司 |
Ｃｄｋ８之醫療性抑制劑及其用途
|
|
CN105744954B
(zh)
|
2013-10-18 |
2021-03-05 |
豪夫迈·罗氏有限公司 |
抗rspo2和/或抗rspo3抗体及其用途
|
|
NZ760065A
(en)
|
2013-12-17 |
2022-12-23 |
Genentech Inc |
Methods of treating cancers using pd-1 axis binding antagonists and taxanes
|
|
CA2934028A1
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
|
US9242965B2
(en)
|
2013-12-31 |
2016-01-26 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
|
|
BR112016021383A2
(pt)
|
2014-03-24 |
2017-10-03 |
Genentech Inc |
Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
|
|
RU2016142476A
(ru)
|
2014-03-31 |
2018-05-07 |
Дженентек, Инк. |
Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
|
|
HRP20192285T1
(hr)
|
2014-03-31 |
2020-03-06 |
F. Hoffmann - La Roche Ag |
Anti-ox40 protutijela i postupci uporabe
|
|
JP6814730B2
(ja)
|
2014-09-05 |
2021-01-20 |
ジェネンテック， インコーポレイテッド |
治療用化合物およびその使用
|
|
CN107073125A
(zh)
|
2014-09-19 |
2017-08-18 |
基因泰克公司 |
Cbp/ep300和bet抑制剂用于治疗癌症的用途
|
|
CN107912040B
(zh)
|
2014-10-10 |
2021-04-06 |
基因泰克公司 |
作为组蛋白脱甲基酶抑制剂的吡咯烷酰胺化合物
|
|
CN107109484B
(zh)
|
2014-11-03 |
2021-12-14 |
豪夫迈·罗氏有限公司 |
用于ox40激动剂治疗的功效预测和评估的方法和生物标志物
|
|
AU2015343337A1
(en)
|
2014-11-03 |
2017-06-15 |
Genentech, Inc. |
Assays for detecting T cell immune subsets and methods of use thereof
|
|
KR20170072343A
(ko)
|
2014-11-06 |
2017-06-26 |
제넨테크, 인크. |
Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법
|
|
MA40943A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
|
MA40940A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
|
WO2016077375A1
(en)
|
2014-11-10 |
2016-05-19 |
Genentech, Inc. |
Bromodomain inhibitors and uses thereof
|
|
MX2017006320A
(es)
|
2014-11-17 |
2017-08-10 |
Genentech Inc |
Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
|
|
CN107531690B
(zh)
|
2014-11-27 |
2020-11-06 |
基因泰克公司 |
用作CBP和/或EP300抑制剂的4,5,6,7-四氢-1H-吡唑并[4,3-c]吡啶-3-胺化合物
|
|
WO2016100347A2
(en)
|
2014-12-15 |
2016-06-23 |
The Regents Of The University Of Michigan |
Small molecule inhibitors of egfr and pi3k
|
|
MX2017006864A
(es)
|
2014-12-23 |
2017-08-28 |
Genentech Inc |
Composiciones y métodos para tratar y diagnosticar cánceres resistentes a la quimioterapia.
|
|
EP3240908A2
(en)
|
2014-12-30 |
2017-11-08 |
F. Hoffmann-La Roche AG |
Methods and compositions for prognosis and treatment of cancers
|
|
EP3242874B1
(en)
|
2015-01-09 |
2018-10-31 |
Genentech, Inc. |
Pyridazinone derivatives and their use in the treatment of cancer
|
|
JP6889661B2
(ja)
|
2015-01-09 |
2021-06-18 |
ジェネンテック， インコーポレイテッド |
４，５−ジヒドロイミダゾール誘導体およびヒストンジメチラーゼ（ｋｄｍ２ｂ）インヒビターとしてのその使用
|
|
CN107406414B
(zh)
|
2015-01-09 |
2022-04-19 |
基因泰克公司 |
作为用于治疗癌症的组蛋白脱甲基酶kdm2b的抑制剂的(哌啶-3-基)(萘-2-基)甲酮衍生物
|
|
CN107531692B
(zh)
|
2015-01-29 |
2020-12-25 |
基因泰克公司 |
治疗化合物及其用途
|
|
CN107438593B
(zh)
|
2015-01-30 |
2020-10-30 |
基因泰克公司 |
治疗化合物及其用途
|
|
MA41598A
(fr)
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
Composés thérapeutiques de pyridazine et leurs utilisations
|
|
MX2017012805A
(es)
|
2015-04-07 |
2018-04-11 |
Genentech Inc |
Complejo de unión a antígenos con actividad agonista y métodos de uso.
|
|
EP3294770B2
(en)
|
2015-05-12 |
2024-03-20 |
F. Hoffmann-La Roche AG |
Therapeutic and diagnostic methods for cancer
|
|
KR20250151554A
(ko)
|
2015-05-29 |
2025-10-21 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
|
US20170000885A1
(en)
|
2015-06-08 |
2017-01-05 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
|
EP3303399A1
(en)
|
2015-06-08 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Methods of treating cancer using anti-ox40 antibodies
|
|
IL256080B2
(en)
|
2015-06-17 |
2025-06-01 |
Genentech Inc |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
|
WO2017033019A1
(en)
|
2015-08-26 |
2017-03-02 |
Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii (Cnio) |
Condensed tricyclic compounds as protein kinase inhibitors
|
|
JP2018532990A
(ja)
|
2015-09-04 |
2018-11-08 |
オービーアイ ファーマ，インコーポレイテッド |
グリカンアレイおよび使用の方法
|
|
KR20250021613A
(ko)
|
2015-09-25 |
2025-02-13 |
제넨테크, 인크. |
항-tigit 항체 및 이의 이용 방법
|
|
DK3389662T3
(da)
|
2015-12-16 |
2022-02-28 |
Genentech Inc |
Fremgangsmåde til fremstilling af tricykliske PI3K-inhibitorforbindelser og fremgangsmåder til anvendelse af disse til behandling af cancer
|
|
TWI740873B
(zh)
*
|
2015-12-24 |
2021-10-01 |
日商協和麒麟股份有限公司 |
α、β不飽和醯胺化合物
|
|
AR107303A1
(es)
|
2016-01-08 |
2018-04-18 |
Hoffmann La Roche |
Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
|
|
EP3402536A4
(en)
|
2016-01-13 |
2019-07-03 |
Hadasit Medical Research Services And Development Limited |
RADIOACTIVELY MARKED ERLOTINIB ANALOGUES AND USES THEREOF
|
|
KR102500659B1
(ko)
|
2016-02-29 |
2023-02-16 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
|
TWI780045B
(zh)
|
2016-03-29 |
2022-10-11 |
台灣浩鼎生技股份有限公司 |
抗體、醫藥組合物及方法
|
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
|
EP3443004A1
(en)
|
2016-04-14 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Anti-rspo3 antibodies and methods of use
|
|
CA3019921A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
|
CN109072311A
(zh)
|
2016-04-15 |
2018-12-21 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
|
EP3443120A2
(en)
|
2016-04-15 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Methods for monitoring and treating cancer
|
|
AU2017252128B2
(en)
|
2016-04-22 |
2024-06-06 |
Obi Pharma, Inc. |
Cancer immunotherapy by immune activation or immune modulation via Globo series antigens
|
|
US20190151346A1
(en)
|
2016-05-10 |
2019-05-23 |
INSERM (Institute National de la Santé et de la Recherche Médicale) |
Combinations therapies for the treatment of cancer
|
|
CN109476663B
(zh)
|
2016-05-24 |
2021-11-09 |
基因泰克公司 |
用于治疗癌症的吡唑并吡啶衍生物
|
|
JP7160688B2
(ja)
|
2016-05-24 |
2022-10-25 |
ジェネンテック， インコーポレイテッド |
Ｃｂｐ／ｅｐ３００の複素環式インヒビターおよびがんの処置におけるそれらの使用
|
|
CA3026880A1
(en)
|
2016-06-08 |
2017-12-14 |
Xencor, Inc. |
Methods and compositions for inhibiting cd32b expressing cells in igg4-related diseases
|
|
CN109312407A
(zh)
|
2016-06-08 |
2019-02-05 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
|
KR20230117482A
(ko)
|
2016-07-27 |
2023-08-08 |
오비아이 파머 인코퍼레이티드 |
면역원성/치료 글리칸 조성물 및 그의 용도
|
|
JP7121724B2
(ja)
|
2016-07-29 |
2022-08-18 |
オービーアイ ファーマ，インコーポレイテッド |
ヒト抗体、医薬組成物及び方法
|
|
EP3494139B1
(en)
|
2016-08-05 |
2022-01-12 |
F. Hoffmann-La Roche AG |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
|
CN109476748B
(zh)
|
2016-08-08 |
2023-05-23 |
豪夫迈·罗氏有限公司 |
用于癌症的治疗和诊断方法
|
|
IL265759B2
(en)
|
2016-10-06 |
2025-10-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer
|
|
JP2019535250A
(ja)
|
2016-10-29 |
2019-12-12 |
ジェネンテック， インコーポレイテッド |
抗ｍｉｃ抗体及び使用方法
|
|
WO2018094414A1
(en)
|
2016-11-21 |
2018-05-24 |
Obi Pharma, Inc. |
Conjugated biological molecules, pharmaceutical compositions and methods
|
|
PL3589754T3
(pl)
|
2017-03-01 |
2023-10-09 |
F. Hoffmann-La Roche Ag |
Sposoby diagnostyczne i terapeutyczne w chorobach nowotworowych
|
|
JP2020516638A
(ja)
|
2017-04-13 |
2020-06-11 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
がんを処置する方法における使用のための、インターロイキン２イムノコンジュゲート、ｃｄ４０アゴニスト、および任意選択のｐｄ−１軸結合アンタゴニスト
|
|
CN111492245A
(zh)
|
2017-07-21 |
2020-08-04 |
基因泰克公司 |
癌症的治疗和诊断方法
|
|
CN111295394B
(zh)
|
2017-08-11 |
2024-06-11 |
豪夫迈·罗氏有限公司 |
抗cd8抗体及其用途
|
|
KR102811888B1
(ko)
|
2017-09-08 |
2025-05-27 |
에프. 호프만-라 로슈 아게 |
암의 진단 및 치료 방법
|
|
CN107400094B
(zh)
*
|
2017-09-08 |
2020-04-03 |
贾玉庆 |
喹唑啉基羧酸酯类化合物及其用途
|
|
WO2019084395A1
(en)
|
2017-10-27 |
2019-05-02 |
University Of Virginia Patent Foundation |
COMPOUNDS AND METHODS FOR REGULATING, LIMITING OR INHIBITING AVIL EXPRESSION
|
|
WO2019090263A1
(en)
|
2017-11-06 |
2019-05-09 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
EP3740756A4
(en)
|
2018-01-15 |
2021-10-27 |
Epiaxis Therapeutics Pty Ltd |
MEANS AND METHOD OF PREDICTING RESPONSE TO THERAPY
|
|
MY210421A
(en)
|
2018-01-26 |
2025-09-22 |
Exelixis Inc |
Compounds for the treatment of kinase-dependent disorders
|
|
IL302626B2
(en)
|
2018-01-26 |
2025-12-01 |
Exelixis Inc |
Compounds for the treatment of kinase-dependent disorders
|
|
MA51679A
(fr)
|
2018-01-26 |
2020-12-02 |
Exelixis Inc |
Composés destinés au traitement de troubles dépendant de la kinase
|
|
MX2020008882A
(es)
|
2018-02-26 |
2021-01-08 |
Genentech Inc |
Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
|
|
US20210363590A1
(en)
|
2018-05-21 |
2021-11-25 |
Nanostring Technologies, Inc. |
Molecular gene signatures and methods of using same
|
|
AU2019288728A1
(en)
|
2018-06-23 |
2021-01-14 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
|
TWI853822B
(zh)
|
2018-06-27 |
2024-09-01 |
台灣浩鼎生技股份有限公司 |
用於糖蛋白工程的糖苷合成酶變體及其使用方法
|
|
BR112021000673A2
(pt)
|
2018-07-18 |
2021-04-20 |
Genentech, Inc. |
métodos para tratar um indivíduo com câncer de pulmão, kits, anticorpo anti-pd-l1 e composições
|
|
TW202024023A
(zh)
|
2018-09-03 |
2020-07-01 |
瑞士商赫孚孟拉羅股份公司 |
治療性化合物及其使用方法
|
|
CN112955747A
(zh)
|
2018-09-19 |
2021-06-11 |
豪夫迈·罗氏有限公司 |
膀胱癌的治疗和诊断方法
|
|
MX2021003213A
(es)
|
2018-09-21 |
2021-05-12 |
Genentech Inc |
Metodos de diagnostico para cancer de mama triple negativo.
|
|
WO2020068867A1
(en)
|
2018-09-25 |
2020-04-02 |
Black Diamond Therapeutics, Inc. |
Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
|
|
US12404540B2
(en)
|
2018-10-17 |
2025-09-02 |
The University Of Queensland |
Epigenetic biomarker and uses therefor
|
|
EP3867646A1
(en)
|
2018-10-18 |
2021-08-25 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
|
CN109608334B
(zh)
*
|
2019-01-11 |
2021-07-13 |
盐城通海生物科技有限公司 |
一种合成4-甲氧基巴豆酸甲酯的方法
|
|
EP3921443A1
(en)
|
2019-02-08 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for cancer
|
|
BR112021016923A2
(pt)
|
2019-02-27 |
2021-11-03 |
Genentech Inc |
Métodos para tratar um paciente com câncer hematológico, métodos para tratar um paciente com mm recidivante ou refratário, métodos para tratar um paciente tendo um lnh recidivante ou refratário e kits
|
|
WO2020172712A1
(en)
|
2019-02-27 |
2020-09-03 |
Epiaxis Therapeutics Pty Ltd |
Methods and agents for assessing t-cell function and predicting response to therapy
|
|
WO2020223233A1
(en)
|
2019-04-30 |
2020-11-05 |
Genentech, Inc. |
Prognostic and therapeutic methods for colorectal cancer
|
|
TWI879768B
(zh)
|
2019-05-03 |
2025-04-11 |
美商建南德克公司 |
用抗pd-l1抗體治療癌症之方法
|
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
|
WO2021030711A1
(en)
|
2019-08-15 |
2021-02-18 |
Black Diamond Therapeutics, Inc. |
Alkynyl quinazoline compounds
|
|
KR20220057563A
(ko)
|
2019-09-04 |
2022-05-09 |
제넨테크, 인크. |
Cd8 결합제 및 이의 용도
|
|
US12371428B2
(en)
|
2019-09-26 |
2025-07-29 |
Exelixis, Inc. |
Pyridone compounds and methods of use
|
|
TW202126690A
(zh)
|
2019-09-27 |
2021-07-16 |
美商建南德克公司 |
用抗ｔｉｇｉｔ和抗ｐｄ－ｌ１拮抗劑抗體給藥治療
|
|
JP2023511472A
(ja)
|
2019-10-29 |
2023-03-20 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療のための二官能性化合物
|
|
CN115066613A
(zh)
|
2019-11-06 |
2022-09-16 |
基因泰克公司 |
用于治疗血液癌症的诊断和治疗方法
|
|
EP4058435A1
(en)
|
2019-11-13 |
2022-09-21 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
PE20221511A1
(es)
|
2019-12-13 |
2022-10-04 |
Genentech Inc |
Anticuerpos anti-ly6g6d y metodos de uso
|
|
AU2020408562A1
(en)
|
2019-12-20 |
2022-06-23 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
JP2023511595A
(ja)
|
2020-01-27 |
2023-03-20 |
ジェネンテック， インコーポレイテッド |
抗ｔｉｇｉｔアンタゴニスト抗体を用いたがんを処置するための方法
|
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
|
EP4127724A1
(en)
|
2020-04-03 |
2023-02-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
JP2023523450A
(ja)
|
2020-04-28 |
2023-06-05 |
ジェネンテック， インコーポレイテッド |
非小細胞肺がん免疫療法のための方法及び組成物
|
|
CA3181820A1
(en)
|
2020-06-16 |
2021-12-23 |
Genentech, Inc. |
Methods and compositions for treating triple-negative breast cancer
|
|
IL298946A
(en)
|
2020-06-18 |
2023-02-01 |
Genentech Inc |
Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
|
|
CN115997123A
(zh)
|
2020-06-30 |
2023-04-21 |
国家医疗保健研究所 |
用于预测实体癌患者在术前辅助治疗后复发和/或死亡风险的方法
|
|
JP7741831B2
(ja)
|
2020-06-30 |
2025-09-18 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
術前補助療法及び根治手術後の固形がんを患っている患者の再発及び／又は死亡のリスクを予測するための方法
|
|
CN111848584A
(zh)
*
|
2020-07-10 |
2020-10-30 |
江南大学 |
一种多取代喹唑啉类化合物及其应用
|
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
JP2023536602A
(ja)
|
2020-08-03 |
2023-08-28 |
ジェネンテック， インコーポレイテッド |
リンパ腫のための診断及び治療方法
|
|
EP4196612A1
(en)
|
2020-08-12 |
2023-06-21 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
WO2022047243A1
(en)
|
2020-08-27 |
2022-03-03 |
Enosi Life Sciences Corp. |
Methods and compositions to treat autoimmune diseases and cancer
|
|
US12162893B2
(en)
|
2020-09-23 |
2024-12-10 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
IL301547A
(en)
|
2020-10-05 |
2023-05-01 |
Genentech Inc |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2022133345A1
(en)
|
2020-12-18 |
2022-06-23 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
IL303965A
(en)
|
2020-12-22 |
2023-08-01 |
Mekanistic Therapeutics Llc |
Transmuted heteroaryl aminobenzyl compounds as EGFR and/or PI3K inhibitors
|
|
PE20231505A1
(es)
|
2021-02-12 |
2023-09-26 |
Hoffmann La Roche |
Derivados de tetrahidroazepina biciclicos para el tratamiento del cancer
|
|
EP4294804A1
(en)
|
2021-02-19 |
2023-12-27 |
Exelixis, Inc. |
Pyridone compounds and methods of use
|
|
JP2024515204A
(ja)
*
|
2021-04-22 |
2024-04-05 |
ボロノイ インコーポレイテッド |
ヘテロアリール誘導体化合物およびその用途
|
|
EP4347603A1
(en)
|
2021-05-25 |
2024-04-10 |
Erasca, Inc. |
Sulfur-containing heteroaromatic tricyclic kras inhibitors
|
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
|
JP2024528697A
(ja)
|
2021-07-20 |
2024-07-30 |
エイジーエス・セラピューティクス・ソシエテ・パール・アクシオン・サンプリフィエ |
微細藻類由来の細胞外小胞、その調製および使用
|
|
WO2023018699A1
(en)
|
2021-08-10 |
2023-02-16 |
Erasca, Inc. |
Selective kras inhibitors
|
|
CN115894455B
(zh)
*
|
2021-09-30 |
2024-04-19 |
北京赛特明强医药科技有限公司 |
一种喹唑啉类化合物、组合物及其应用
|
|
US12275745B2
(en)
|
2021-11-24 |
2025-04-15 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
JP2024541508A
(ja)
|
2021-11-24 |
2024-11-08 |
ジェネンテック， インコーポレイテッド |
治療用インダゾール化合物およびがんの治療における使用方法
|
|
WO2023128350A1
(ko)
*
|
2021-12-30 |
2023-07-06 |
주식회사 비투에스바이오 |
헤테로아릴 유도체 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
|
|
WO2023144127A1
(en)
|
2022-01-31 |
2023-08-03 |
Ags Therapeutics Sas |
Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
|
|
KR20240169042A
(ko)
|
2022-04-01 |
2024-12-02 |
제넨테크, 인크. |
항-fcrh5/항-cd3 이중특이성 항체로 치료하기 위한 투약법
|
|
AU2022458320A1
(en)
|
2022-05-11 |
2024-11-28 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
IL317449A
(en)
|
2022-06-07 |
2025-02-01 |
Genentech Inc |
Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist
|
|
EP4554978A1
(en)
|
2022-07-13 |
2025-05-21 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
IL318252A
(en)
|
2022-07-19 |
2025-03-01 |
Genentech Inc |
Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies
|
|
CN119677732A
(zh)
|
2022-08-11 |
2025-03-21 |
豪夫迈·罗氏有限公司 |
双环四氢氮杂䓬衍生物
|
|
CR20250043A
(es)
|
2022-08-11 |
2025-03-25 |
Hoffmann La Roche |
Derivados bicíclicos de tetrahidrotiazepina
|
|
PE20251399A1
(es)
|
2022-08-11 |
2025-05-22 |
Hoffmann La Roche |
Derivados de tetrahidrotiazepina biciclicos
|
|
JP2025526683A
(ja)
|
2022-08-11 |
2025-08-15 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
二環式テトラヒドロチアゼピン誘導体
|
|
JP2025538859A
(ja)
|
2022-10-21 |
2025-12-02 |
公益財団法人川崎市産業振興財団 |
非吸着性またはスーパーステルス小胞
|
|
WO2024088808A1
(en)
|
2022-10-24 |
2024-05-02 |
Ags Therapeutics Sas |
Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof
|
|
TW202426505A
(zh)
|
2022-10-25 |
2024-07-01 |
美商建南德克公司 |
癌症之治療及診斷方法
|
|
TW202434206A
(zh)
|
2023-02-17 |
2024-09-01 |
美商伊瑞斯卡公司 |
Ｋｒａｓ抑制劑
|
|
TW202448949A
(zh)
|
2023-05-05 |
2024-12-16 |
美商建南德克公司 |
用抗ｆｃｒｈ５／抗ｃｄ３雙特異性抗體進行治療之給藥
|
|
WO2024254455A1
(en)
|
2023-06-08 |
2024-12-12 |
Genentech, Inc. |
Macrophage signatures for diagnostic and therapeutic methods for lymphoma
|
|
WO2025024257A1
(en)
|
2023-07-21 |
2025-01-30 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
WO2025049277A1
(en)
|
2023-08-25 |
2025-03-06 |
Genentech, Inc. |
Methods and compositions for treating non-small cell lung cancer comprising an anti-tigit antagonist antibody and a pd-1 axis binding antagonist
|
|
WO2025176847A1
(en)
|
2024-02-21 |
2025-08-28 |
Ags Therapeutics Sas |
Ocular delivery of active agents via microalgae extracellular vesicles
|
|
CN118834200A
(zh)
*
|
2024-06-27 |
2024-10-25 |
辽宁大学 |
含酰胺结构的4-苯胺基喹唑啉类化合物及其应用
|
|
WO2026030476A1
(en)
|
2024-07-30 |
2026-02-05 |
Genentech, Inc. |
Precision medicine for optimal dosage of combined therapies systems and methods of use thereof
|
|
WO2026030464A1
(en)
|
2024-07-30 |
2026-02-05 |
Genentech, Inc. |
Dosage regimen for reducing cytokine release syndrome (crs) with anti-fcrh5/anti-cd3 bispecific antibodies in multiple myeloma therapy
|